The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Active Surveillance Compared With Initial Treatment for Men With Low-Risk Prostate Cancer: A Decision Analysis
Open accessAbstract
CONTEXT: In the United States, 192,000 men were diagnosed as having prostate cancer in 2009, the majority with low-risk, clinically localized disease. Treatment of these cancers is associated with substantial morbidity. Active surveillance is an alternative to initial treatment, but long-term outcomes and effect on quality of life have not been well characterized. OBJECTIVE: To examine the quality-of-life benefits and risks of active surveillance compared with initial treatment for men with low-risk, clinically localized prostate cancer. DESIGN AND SETTING: Decision analysis using a simulation model was performed: men were treated at diagnosis with brachytherapy, intensity-modulated radiation therapy (IMRT), or radical prostatectomy or followed up by active surveillance (a strategy of close monitoring of newly diagnosed patients with serial prostate-specific antigen measurements, digital rectal examinations, and biopsies, with treatment at disease progression or patient choice). Probabilities and utilities were derived from previous studies and literature review. In the base case, the relative risk of prostate cancer-specific death for initial treatment vs active surveillance was assumed to be 0.83. Men incurred short- and long-term adverse effects of treatment. PATIENTS: Hypothetical cohorts of 65-year-old men newly diagnosed as having clinically localized, low-risk prostate cancer (prostate-specific antigen level <10 ng/mL, stage ≤T2a disease, and Gleason score ≤6). MAIN OUTCOME MEASURE: Quality-adjusted life expectancy (QALE). RESULTS: Active surveillance was associated with the greatest QALE (11.07 quality-adjusted life-years [QALYs]), followed by brachytherapy (10.57 QALYs), IMRT (10.51 QALYs), and radical prostatectomy (10.23 QALYs). Active surveillance remained associated with the highest QALE even if the relative risk of prostate cancer-specific death for initial treatment vs active surveillance was as low as 0.6. However, the QALE gains and the optimal strategy were highly dependent on individual preferences for living under active surveillance and for having been treated. CONCLUSIONS: Under a wide range of assumptions, for a 65-year-old man, active surveillance is a reasonable approach to low-risk prostate cancer based on QALE compared with initial treatment. However, individual preferences play a central role in the decision whether to treat or to pursue active surveillance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Djavan, B., Waldert, M., Zlotta, A. R., Dobroński, P., Seitz, C., Mesut Remzi, A., BORKOWSKI, A., Schulman, C., & Marberger, M. (2001) · The Journal of Urology · doi:10.1016/s0022-5347(05)65851-x · Cited by 2,048
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Garmo, H., Stark, J. R., Busch, C., Nordling, S., Häggman, M., Andersson, S.-O., Bratell, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011967 · Cited by 1,900
Welch, H. G., & Black, W. C. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq099 · Cited by 1,599
Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., & Loblaw, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2180 · Cited by 1,074
Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
Cooperberg, M. R., Broering, J. M., & Carroll, P. R. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.0133 · Cited by 1,006
Bacon, C. G., Mittleman, M. A., Kawachi, I., Giovannucci, E., Glasser, D. B., & Rimm, E. B. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-3-200308050-00005 · Cited by 832 · cited 1×
“In the base case, patients in active surveillance develop erectile dysfunction and urinary obstructive symptoms at the same rate as age-matched men without prostate cancer in the general population.(22,23) If subsequently treated, they are at the same risk of adverse effects of treatment as men treated initially.”
BackgroundD'Amico, A. V., Manola, J., Loffredo, M., Renshaw, A. A., DellaCroce, A., & Kantoff, P. W. (2004) · JAMA · doi:10.1001/jama.292.7.821 · Cited by 767
Self-citationQuality of Life after Radical Prostatectomy or Watchful Waiting
Steineck, G., Helgesen, F., Adolfsson, J., Dickman, P. W., Johansson, J.-E., Norlén, B. J., & Holmberg, L. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021483 · Cited by 722
Preference-Based EQ-5D Index Scores for Chronic Conditions in the United States
Sullivan, P. W., & Ghushchyan, V. (2006) · Medical Decision Making · doi:10.1177/0272989x06290495 · Cited by 705
Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery
Brenner, D. J., Curtis, R. E., Hall, E. J., & Ron, E. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000115)88:2<398::aid-cncr22>3.0.co;2-v · Cited by 618
Bill-Axelson, A., Holmberg, L., Filen, F., Ruutu, M., Garmo, H., Busch, C., Nordling, S., Haggman, M., Andersson, S.-O., Bratell, S., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn255 · Cited by 603
United States Life Tables, 2019.
Arias, E., & Xu, J. (2022) · PubMed · Cited by 479
Contemporary Trends in Low Risk Prostate Cancer: Risk Assessment and Treatment
Cooperberg, M. R., Broering, J. M., Kantoff, P. W., & Carroll, P. R. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.135 · Cited by 442
Self-citationActive surveillance for the management of prostate cancer in a contemporary cohort
Dall'Era, M. A., Konety, B. R., Cowan, J. E., Shinohara, K., Stauf, F., Cooperberg, M. R., Meng, M. V., Kane, C. J., Perez, N., Master, V. A., et al. (2008) · Cancer · doi:10.1002/cncr.23502 · Cited by 404
D'Amico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M.-H., Kaplan, I., Beard, C. J., Tomaszewski, J. E., Renshaw, A. A., Wein, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.168 · Cited by 389
The Changing Face of Prostate Cancer
Cooperberg, M. R., Moul, J. W., & Carroll, P. R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.9751 · Cited by 318
Anxiety and distress during active surveillance for early prostate cancer
van den Bergh, R. C. N., Essink‐Bot, M., Roobol, M. J., Wolters, T., Schröder, F. H., Bangma, C. H., & Steyerberg, E. W. (2009) · Cancer · doi:10.1002/cncr.24446 · Cited by 230
United States Life Tables, 2021.
Arias, E., Xu, J., & Kochanek, K. D. (2010) · PubMed · Cited by 224
van As, N. J., Norman, A. R., Thomas, K., Khoo, V. S., Thompson, A., Huddart, R. A., Horwich, A., Dearnaley, D. P., & Parker, C. C. (2008) · European Urology · doi:10.1016/j.eururo.2008.02.039 · Cited by 216
Follow-up Prostate Cancer Treatments After Radical Prostatectomy: a Population-Based Study
Lu-Yao, G. L., Potosky, A. L., Albertsen, P. C., Wasson, J. H., Barry, M. J., & Wennberg, J. E. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.3-4.166 · Cited by 196
Self-citationUtilities For Prostate Cancer Health States in Men Aged 60 and Older
Stewart, S. T., Lenert, L., Bhatnagar, V., & Kaplan, R. M. (2005) · Medical Care · doi:10.1097/01.mlr.0000156862.33341.45 · Cited by 169
Self-citationDo Older Men Benefit From Curative Therapy of Localized Prostate Cancer?
Alibhai, S. M. H., Naglie, G., Nam, R., Trachtenberg, J., & Krahn, M. D. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.034 · Cited by 163
Roemeling, S., Roobol, M. J., de Vries, S. H., Wolters, T., Gosselaar, C., van Leenders, G. J. L. H., & Schröder, F. H. (2007) · European Urology · doi:10.1016/j.eururo.2006.11.053 · Cited by 160
The Impact of IMRT and Proton Radiotherapy on Secondary Cancer Incidence
Schneider, U., Lomax, A., Pemler, P., Besserer, J., Ross, D., Lombriser, N., & Kaser‐Hotz, B. (2006) · Strahlentherapie und Onkologie · doi:10.1007/s00066-006-1534-8 · Cited by 136
Barocas, D. A., Cowan, J. E., Smith, J. A. J., Carroll, P. R., & CaPSURE Investigators (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.06.019 · Cited by 134
Pickles, T., Ruether, J. D., Weir, L. M., Carlson, L. E., Jakulj, F., & the SCRN Communication Team (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.06981.x · Cited by 123
Does active surveillance for men with localized prostate cancer carry psychological morbidity?
Whitaker, K. L., Parker, C. C., Dearnaley, D. P., Brewin, C. R., & Watson, M. (2007) · British Journal of Urology · doi:10.1111/j.1464-410x.2007.07009.x · Cited by 115
A Critique of the Decision Analysis for Clinically Localized Prostate Cancer
Beck, J. R., Kattan, M. W., & Miles, B. J. (1994) · The Journal of Urology · doi:10.1016/s0022-5347(17)32409-6 · Cited by 102
A Decision Analysis for Treatment of Clinically Localized Prostate Cancer
Kattan, M. W., Cowen, M. E., & Miles, B. J. (1997) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1997.012005299.x · Cited by 102
Secondary Cancer After Radiotherapy for Prostate Cancer: Should We Be More Aware of the Risk?
Boström, P. J., & Soloway, M. S. (2007) · European Urology · doi:10.1016/j.eururo.2007.07.002 · Cited by 98
Litwin, M. S., Lubeck, D. P., Spitalny, G. M., Henning, J. M., & Carroll, P. R. (2002) · Cancer · doi:10.1002/cncr.10651 · Cited by 91
Grossfeld, G. D., Olumi, A. F., Connolly, J. A., Chew, K., Gibney, J., BHARGAVA, V., Waldman, F. M., & Carroll, P. R. (1998) · The Journal of Urology · doi:10.1097/00005392-199805000-00004 · Cited by 81
Sommers, B. D., Beard, C. J., D'Amico, A. V., Dahl, D. M., Kaplan, I. D., Richie, J. P., & Zeckhauser, R. (2007) · Cancer · doi:10.1002/cncr.23028 · Cited by 80
Dale, W., Basu, A., Elstein, A. S., & Meltzer, D. (2007) · Medical Decision Making · doi:10.1177/0272989x07309639 · Cited by 58
Chung, C. S., Keating, N. L., Yock, T. I., & Tarbell, N. J. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.06.785 · Cited by 56
Interval to Testosterone Recovery After Hormonal Therapy for Prostate Cancer and Risk of Death
D'Amico, A. V., Chen, M., Renshaw, A. A., Loffredo, M. J., & Kantoff, P. W. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.082 · Cited by 49
Self-citationWalsh, P. C. (2005) · The Journal of Urology · doi:10.1016/s0022-5347(05)60498-3 · Cited by 44
Low risk prostate cancer in men under age 65: The case for definitive treatment
Jang, T. L., Yossepowitch, O., Bianco, F. J., & Scardino, P. T. (2007) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2007.05.025 · Cited by 26
Bhatnagar, V., Stewart, S. T., Bonney, W. W., & Kaplan, R. M. (2004) · Urology · doi:10.1016/j.urology.2003.08.011 · Cited by 26
Self-citationA decision analysis of alternative treatment strategies for clinically localized prostate cancer
Fleming, C. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500200064035 · Cited by 4
Cited by
Radical Prostatectomy versus Observation for Localized Prostate Cancer
Wilt, T. J., Brawer, M. K., Jones, K. M., Barry, M. J., Aronson, W. J., Fox, S., Gingrich, J. R., Wei, J. T., Gilhooly, P., Grob, B. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113162 · Cited by 1,770
Self-citationEarly Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Self-citationEvidence for Health Decision Making — Beyond Randomized, Controlled Trials
Frieden, T. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1614394 · Cited by 770
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Klein, E. A., Cooperberg, M. R., Magi-Galluzzi, C., Simko, J. P., Falzarano, S. M., Maddala, T., Chan, J. M., Li, J., Cowan, J. E., Tsiatis, A. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.004 · Cited by 659
Metadata
- Authors
- Hayes, J. H., Ollendorf, D. A., Pearson, S. D., Barry, M. J., Kantoff, P. W., Stewart, S. T., Bhatnagar, V., Sweeney, C. J., Stahl, J. E., & McMahon, P. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-12-01
- Volume
- 304
- Issue
- 21
- Pages
- 2373
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2070912263
- Cited by
- 257
- References
- 43
- FWCI
- 26.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.